LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC

LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC

Non-small cell lung carcinoma (NSCLC) patients who initially received tyrosine kinase inhibitor (TKI) therapy often acquired resistance via multiple complex mechanisms. The amplification of FGF3/4/19/CCND1 on chromosome 11q13 was found in many cancers with TKI resistance. However, the role of these...

Full description

Bibliographic Details
Main Authors: Dongcheng Liu, Hongguang Liu, Jiadi Gan, Shinuan Zeng, Fuhua Zhong, Bin Zhang, Zhe Zhang, Siyu Zhang, Lu Jiang, Guangsuo Wang, Yixin Chen, Feng-Ming Spring Kong, Wenfeng Fang, Lingwei Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
gefitinib resistance
FGF3/4/19/CCND1 amplification
NSCLC
LY2874455
abemaciclib
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.918317/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.918317/full

Similar Items